Effect of citicoline adjuvant therapy on mild cognitive impairment in Parkinson’s disease

To investigate the effect of citicoline adjuvant therapy on mild cognitive impairment (MCI) in Parkinson’s disease (PD) (PD-MCI) and its influence on plasma phospholipid (PL) levels in PD-MCI patients. The demographic data on 81 PD-MCI patients among 185 idiopathic PD patients who participated in the research from November 2012 to December 2014 were collected, and which were randomly divided into a citicoline treatment group and a control group. Patients in the citicoline treatment group received citicoline sodium capsules orally (200 mg) three times daily (t.i.d.), in addition to the basic drug treatment. MoCA, SCOPA-COG evaluations and plasma PL level measurements were performed after 12 and 18 months of treatment. The MoCA and SCOPA-COG scores showed a significant difference between the treatment and control groups after 12 and 18 months of treatment (P<0.05, P<0.01), and the plasma PL levels in the treatment group, compared to the control group, significantly decreased after 12 and 18 months of treatment (P<0.01, P<0.001). Citicoline adjuvant therapy might delay the cognitive function decline rate in PD-MCI patients and reduce their plasma PL levels. Suggesting that this treatment has probablely neuroprotective effects.